“I’m ecstatic to announce a full season effort in the NASCAR Xfinity Series with JP Motorsports in the #45 Prevagen Toyota Camry,” said Bilicki. “I have gained a lot of valuable experience over the past two years by racing at different tracks and with different teams, but it will be nice to show up to every race this year with the same team. I come from a road course racing background, so there are still several NASCAR tracks that I have yet to race. It feels great to have the business side of things done before the season starts, so now I can focus solely on driving. It will be a year full of learning, but we have good equipment and cars and will be competitive from the start.”“This certainly wouldn’t be possible without Prevagen. They were my primary sponsor at several NASCAR races last year, so it will be great to have them for a full season this year. The company began in a building only five miles from my house, so I find that very cool. They are still located in Wisconsin, so I hope to be able to grow the Wisconsin Prevagen brand throughout the 2018 season.”
“We’re very pleased to be able to support Josh for the entire racing season this year,” said Todd Olson, market development manager at Quincy Bioscience. “He’s proven himself to be a great competitor and we’re looking forward to seeing how Josh turns last years’ experience into some exciting finishes this year.”
Tune into the PowerShares QQQ 300 at the Daytona International Speedway on Saturday, February 17th at 2:30 p.m. ET on FS1 to see Josh Bilicki try his hand at restrictor plate racing for the first time. (Koelle,2018)
About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin, focused on the discovery, development, and commercialization of novel technologies to support brain health in aging, with a specific emphasis on memory support and cognitive health. Quincy Bioscience is set apart by its cutting-edge applications of the patented protein apoaequorin, which has been tested to show improvements in cognition and memory in clinical trials.
Comments
Post a Comment